The company is a leading provider of an AI-powered precision oncology platform transforming biomarker discovery and treatment decisions. Nucleai’s platform leverages unique tissue datasets to produce insights into cancer biology, increasing clinical trial efficacy, and improving patient care. Nucleai works with leading pharmaceutical companies, licensing its research platform for internal use, and collaborating in biomarkers discovery projects.
B2B
26 to 50
Series A
$11.5 M
Scaling Up
2017
Information Services
Healthcare
N/A
N/A
IT and Security
Yes
Active
Machine Learning
Software
N/A
AI/ML Professionals
Want to work at Nucleai?
We can introduce you to the right person at Nucleai
6
1
$33M
Company was founded 2017 and it took almost 5 years (Mar 2022) to raise first external round
Investors
Interested in researching Nucleai?
We have plenty of data and we can help. Our deal sourcing platform can help you perform more research about Nucleai
Avi Veidman
CEO
Eliron Amir
COO
Albert Achtenberg
CTO
Potential Customers
Interested in what they do or partnership?
Learn more about how they work